Application value and research progress in thoracic radiotherapy for extensive-stage small cell lung cancer
10.3760/cma.j.cn113030-20230731-00031
- VernacularTitle:广泛期小细胞肺癌胸部放疗的应用价值及研究进展
- Author:
Chaonan ZHANG
1
;
Lei DENG
;
Zongmei ZHOU
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科，北京 100021
- Keywords:
Small cell lung carcinoma;
Radiotherapy;
Radioimmunotherapy
- From:
Chinese Journal of Radiation Oncology
2024;33(4):365-370
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) is characterized by rapid proliferation and high propensity for local recurrence and widespread metastasis, which yields extremely poor prognosis. Approximately 2/3 of patients present with extensive-stage disease (ES-SCLC) at initial diagnosis. For ES-SCLC, the combination platinum-based chemotherapy has been the standard regimen for the past few decades. In the era of chemotherapy, multiple studies have shown the benefit of thoracic radiotherapy (TRT) for patients who responded to chemotherapy. However, with the first-line treatment of ES-SCLC shifting into the immune era, as well as the advances in diagnostic imaging modality and radiation technology, the benefit of TRT has caused a widespread controversy. In this article, the value of TRT for ES-SCLC and the latest progress in the radioimmunotherapy combination mode for ES-SCLC were reviewed.
